21 publications in total
A Phase I/II study of first-in-human trial of Glecirasib (KRAS G12C inhibitor) in advanced solid tumors
2022 annual meeting of American Society of Clinical Oncology (ASCO)
Jun, 2022

Pages

Platform & Pipeline

Partnership